SFCA3007: Significantly Greater Improvements in Pre-Dose FEV1 Seen with FP250 vs. Placebo

*Pɘ.001 vs PLA

Endpoint

? FEV1 (ml)

*

(1%)

(11%)

Previous slide

Next slide

Back to first slide

View graphic version